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Prothrombin complex concentrates (PCCs) are purified drug products with hemostatic 
activity derived from a plasma pool.1 The early 
PCC products contained three clotting factors, 
II, IX, and X; however, some of the newer for-
mulations, available in some European coun-
tries, but not the United States are deemed ‘‘four 
factor concentrates’’ as they also contain factor 
VII in a significant concentration. Today, PCCs 
contain vitamin K-dependent coagulation fac-
tors (II, VII, IX and X), and are mainly indicated 
for the reversal of the anticoagulant effect of vi-
tamin K antagonists (VKAs) acenocoumarol and 
warfarin. In this indication, these compounds 
show a superior effect to fresh frozen plasma 
(FFP) in decreasing hemorrhage and/or transfu-
sion rate in patients under VKAs treatment with 
active bleeding or who require an invasive surgi-
cal procedure.1-3
Indications for prescription of VKAs have 
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A B S T R AC T
Prothrombin complex concentrates (PCCs) are purified drug products with hemostatic activity derived from a 
plasma pool. Today, PCCs contain a given and proportional amount of four non-activated vitamin K-dependent 
coagulation factors (II, VII, IX, and X), a variable amount of anticoagulant proteins (proteins C and S, and in some 
antithrombin) and low-dose heparin. In some countries PCC products contained only three clotting factors, II, IX, 
and X. Dosage recommendations are based on IU of F-IX, so that one IU of F-IX represents the activity of F-IX 
in 1 mL of plasma. Reversion of the anticoagulant effect of vitamin K antagonists (VKAs) in cases of symptomatic 
overdose, active bleeding episodes, or need for emergency surgery is the most important indication for PCCs and 
this effect of PCCs appears to be more complete and rapid than that caused by administration of fresh frozen plasma. 
They may be considered as safe preparations if they are used for their approved indications at the recommended 
dosage with adequate precautions for administration, and have been shown to be effective for reversing the effect 
of VKAs. Their adequate use based on decision algorithms in the perioperative setting allows a rapid normalization 
of International Normalized Ratio (INR) for performing emergency surgery, minimizing bleeding risk. This review 
aims to propose two algorithms for to use the PCCs in the perioperative setting, one to calculate the PCCs dose to 
be administered in a bleeding patient and / or immediately before urgent surgery, based on patient’s clinical status, 
prior INR and INR target and another for reversing the action of oral anticoagulants depending on urgency of 
surgery. (Minerva Anestesiol 2011;77:1-2)
Key words: Prothrombin complex concentrates - Blood coagulation factors - Hemorrhage - Algorithms.
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been expanded in recent years. This, together 
with the increased life expectation, has mark-
edly risen the number of patients treated to ap-
proximately 700000 in Spain, which represents 
approximately 1.3% of the total population.4 
The most significant complication derived from 
chronic anticoagulation is severe hemorrhage, 
whose incidence is variable, but may range from 
0.9 and 1.35/100 patient/year. Among them, 
it is necessary to highlight the incidence rate 
of intracranial hemorrhage and fatal bleeding, 
which range from 0.46 and 0.7/100 patient/year 
and from 0.25 and 0.3/100 patient/year respec-
tively.5-10 Factors related to an increased risk of 
bleeding include anticoagulation intensity, vari-
ability, and duration; age; patient comorbidity; 
and concomitant treatments. Risk of bleeding 
significantly increases when INR (international 
standardized ratio) is 4.5 or greater.6 PCCs have 
also been used to correct both congenital and 
acquired deficiencies of specific factors (particu-
larly II and IX), and their use in perioperative 
management of massive bleeding is becoming 
widespread even in non-anticoagulated patients, 
particularly when availability of FFP is limited. 
Unfortunately, there are no controlled clinical 
trials that allow for making recommendations to 
support use of PCCs for indications not listed in 
the prescription information, and most of these 
recommendations are based on retrospective, 
observational studies, in clinical cases, or in ex-
pert recommendations.
This document reviews the different PCCs 
available in our setting, their established and po-
tential indications, their dosage, adverse effects, 
and precautions to be considered when used in 
Table I.—Levels of scientific evidence and grades of recommendation based on the GRADE methodology used in this article.
Grade of
Recommendation Description
Benefits vs. risk
and burdens
Methodological quality of 
supporting evidence Implications
1A Strong recommendation, 
high-quality evidence
Benefits clearly outweigh 
risk and burdens, or vice 
versa
RCTs without important 
limitations or overwhelm-
ing evidence from obser-
vational studies
Strong recommendation, 
can apply to most patients 
in most circumstances 
without reservation
1B Strong recommendation, 
moderate quality evidence
Benefits clearly outweigh 
risk and burdens, or vice 
versa
RCTs with important 
limitations (inconsistent 
results, methodological 
flaws, indirect or impre-
cise) or exceptional strong 
evidence from observa-
tional studies
Strong recommendation, 
can apply to most patients 
in most circumstances 
without reservation
1C Strong recommendation, 
low-quality or very low-
quality evidence
Benefits clearly outweigh 
risk and burdens, or vice 
versa
Observational studies or 
case series
Strong recommendation 
but may change when 
higher quality evidence 
becomes available
2A Weak recommendation, 
high-quality evidence
Benefits closely balanced 
with risk and burden, or 
vice versa
RCTs without important 
limitations or overwhelm-
ing evidence from obser-
vational studies
Weak recommendation, 
best action may differ de-
pending on circumstances 
or patients’ or societal 
values
2B Weak recommendation, 
moderate quality evidence
Benefits closely balanced 
with risk and burden, or 
vice versa
RCTs with important 
limitations (inconsistent 
results, methodological 
flaws, indirect or impre-
cise) or exceptional strong 
evidence from observa-
tional studies
Weak recommendation, 
best action may differ de-
pending on circumstances 
or patients’ or societal 
values
2C Weak recommendation, 
low-quality or very low-
quality evidence
Uncertainty in the es-
timates of benefits and 
burden; benefits, risk and 
burden may be closely bal-
anced
Observational studies or 
case series
Very weak recommenda-
tions; other alternatives 
may be equally reasonable
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Approximately 15 preparations are currently 
marketed worldwide, but in our setting there are 
three commercial PCC preparations available 
(Prothromplex NF®-/Baxter SL, Beriplex®-CSL 
Behring, and Octaplex®-Octapharma SA). These 
are very similar but not identical, each having 
some different characteristics (Table II). Clinical 
use of all of them is practically superimposable, 
and there is no evidence of superiority of one 
over another. The Summaries of Product Char-
acteristics of the PCCs available in Spain may be 
consulted at the website of the Spanish Agency 
for Medicinal Products and Medical Devices 
(www.emps.es).
Today, PCCs contain a given and propor-
tional amount of four non-activated vitamin K-
dependent coagulation factors (II, VII, IX, and 
X), a variable amount of anticoagulant proteins 
(proteins C and S, and in some antithrombin) 
and low-dose heparin (Table II).13 Dosage rec-
ommendations are based on IU of F-IX, so that 
one IU of F-IX represents the activity of F-IX in 
1 mL of plasma.
All four factors provided by PCCs are essential 
for the hemostatic process. Thus, the tissue fac-
tor/factor VIIa complex that activates factors IX 
and X is produced during the starting phase of 
the coagulation process. The formed F-Xa gener-
ates a small amount of thrombin (by activation 
the perioperative period. When scientific evi-
dence is available, this will be provided using the 
GRADE methodology,11 recommending (Grade 
1) or suggesting (Grade 2) the use of PCCs based 
on whether the degree of evidence in the avail-
able literature is strong (A), moderate (B) or low 
(C) (Table I).
Characteristics
PCCs started to be used for clinical purposes 
in the early 1970s as a source of F-IX for treat-
ing patients with type B hemophilia. They were 
obtained using the Cohn fractionation technique 
or calcium absorption of plasma. Since they were 
initially used in 1976 to successfully revert excess 
anticoagulation secondary to VKAs,12 PCCs have 
been effectively used for restoring hemostatic 
competence in patients anticoagulated with these 
drugs. These agents are enriched in prothrombin 
and factors VII, IX, and X, and also contain trace 
amounts of factors VIII, VIIa and IXa. However, 
the specific content of each clotting factor, par-
ticularly FVII, varies by concentrate. The anti-
coagulant vitamin K-dependent factors protein 
C and protein S are also present at variable con-
centrations.13 Over time, both composition and 
preparation of PCCs have evolved to make them 
more effective and safe for administration.
Table II.—Contents in coagulation and anticoagulant factors of fresh frozen plasma and prothrombin complex concentrates 
marketed in Spain (data in IU/mL).
FFP (*)
(IU/mL)
PROTHROMPLEX INF
(IU/mL)
BERIPLEX
(IU/mL)
OCTAPLEX
(IU/mL)
F-II
F-VII
F-IX
F-X
Protein C
Protein S
AT
Heparin
Viral inactivation/
elimination
1
1
1
1
1
1
1
-
MB
-
30
25
30
30
>20
14-16
0.75-1.5
15.5
Steam treatment
Nanofiltration
20-48
10-25
20-31
22-60
15-45
13-26
9.2-1.5
0.4-2.0
Pasteurization
Nanofiltration
11-38
9-24
25
18-30
7-31
7-32
-
5-12.5
Solvent-detergent
Nanofiltration
FFP: fresh frozen plasma; MB: Methylene blue; AT: Antithrombin.
(*) By definition, FFP consists of 1 IU/mL of each of the stable and labile coagulation factors (+/-25%), except for fibrino-
gen.
(Prothrombin complex concentrate data based on manufacturer information and on the labels of the different products 
available at www.agemed.es)
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er volume of FFP (close to 30 mL/kg), which 
represents in practice a plasma volume replace-
ment.20, 21 Although there are various factors in-
fluencing this effect, one of the most important 
is variability in the concentration of coagulation 
factors present in FFP, which may experience a 
loss of factors close to 25% during the inactiva-
tion process. Loss of factors related to storage at 
-30ºC, particularly in the long term, should also 
be considered.22 One unit of PCC usually has a 
concentration of coagulation factors per volume 
unit approximately 25-30 times greater than 
FFP (Table II), which means that a 600 IU vial 
of PCC is equivalent to approximately 600 mL 
of freshly drawn, unmanipulated plasma. Dif-
ferences between PCCs and FFP may be sum-
marized by saying that PCCs provide a more 
complete reversing effect, allow for immediate 
availability (they do not require blood typing 
or thawing as FFP), are safer because they do 
not induce transfusion-related acute lung injury 
(TRALI) and are administered faster (their vol-
ume is much smaller than their FFP equivalent).
This last feature is very useful in pediatric and 
neonatal patients who have a limited total blood 
volume and high risk of overload, although in 
the prescription information appears there is no 
experience in children (Beriplex®) or they has 
not been used in cerebral hemorrhage in ne-
onates with deficiency of vitamin k (Octaplex®). 
In general, in the children the experience of use 
is insufficient, but it’s true that the specific fac-
tors should be used in cases of selective deficits, 
if they are available (Table III).21-23
Indications
Accepted indications
Administration of PCCs is indicated for:
1) prophylaxis and treatment for bleeding in 
patients with congenital deficiencies of factors of 
the prothrombin complex (factors II, VII, IX, 
and X) in the absence of specific factors (recom-
mendation 1B);
2) prophylaxis and treatment of bleeding in 
patients with acquired deficiencies of factors of 
the prothrombin complex (overall recommenda-
tion in this indication 1B).
of prothrombin) that amplifies and propagates 
the procoagulant signal until the so-called pro-
thrombinase complex (Xa and Va, phospholipids 
and calcium) is formed. This complex induces 
quick and effective formation of large amounts 
of thrombin and, subsequently, fibrinogen at the 
endothelial lesion site.14, 15
Following administration, a rapid (within 30 
minutes) and sustained correction occurs of he-
mostatic changes secondary to deficiency of vita-
min K-dependent coagulation factors, leading to 
normalization (<1.3) of the international stand-
ardized ratio (INR) of prothrombin time if an 
adequate dose has been given.16, 17 INR stands 
for International Normalized Ratio and it’s really 
just the standard unit used to report the result of 
a PT test. In the 1980s the World Health Orga-
nization determined that patients may be at risk 
because the results of a PT test would vary from 
one laboratory to another. In order to standard-
ize the results between labs, the INR was created. 
The INR, unlike PT, takes into consideration the 
sensitivity of the thromboplastin reagent and has 
accepted therapeutic limits for different antico-
agulation indications.
The INR is calculated from the following for-
mula: INR = (Patient PT/Normal PT)ISI
Normal PT is obtained by averaging the PTs 
of a group of healthy individuals not taking 
medications. The International Sensitivity In-
dex (ISI) is provided by the manufacturer of the 
thromboplastin and is lot specific and somewhat 
instrument dependent. On normal conditions of 
coagulation, the INR is around 1 and the INR 
range will vary from person to person depending 
on a variety of factors. The most common INR 
target range for someone on warfarin is some-
where between 2.0 and 4.0. INRs of 5 or more 
typically are avoided because the risk of bleeding 
increases significantly at INRs above 5.18
This reversing effect of PCCs appears to be 
more complete and rapid than that caused by 
administration of FFP. It should be noted that 
the reversing action of FFP on INR is dose-de-
pendent but not linear: standard doses of FFP 
(15-20 mL/kg) achieve a significant INR re-
duction, but the normal range19 is not usually 
achieved. However, complete normalization of 
these values would require provision of a great-
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associated to a decreased plasma activity of depend-
ent factors from 6-8 h post-administration. This is 
because both warfarin and acenocoumarol have a 
longer half-life than factors present in PCCs. We 
therefore recommend concomitant administration 
of PCCs with vitamin K for reversing VKAs (1B).
 — A 500-600 IU dose of PCC (approxi-
mately 10 IU/kg) may be effective for reversing 
an INR <5, but individualization of the dose 
based on weight and initial INR is recommend 
in all patients (1B).
Potential indications
Unavailability of FFP
When fresh plasma is indicated but not avail-
able, use of PCCs is recommended (1B). In pa-
tients who refuse transfusion of FFP, PCCs may 
be an alternative.
Risk of hypervolemia
As noted above, the dose needed for adequate 
reversion of the anticoagulant effect of VKAs 
may require administration of a substantial vol-
ume when FFP is used (up to two liters in an 
average adult patient), which may be associated 
with complications related to volume overload.29 
We suggest use of PCCs in patients who require 
a supply of factors and have a risk of volume 
overload (2C).
Reversion of the anticoagulant effect of VKAs 
in cases of symptomatic overdose, active bleed-
ing episodes, or need for emergency surgery is 
the most important indication for PCCs.1, 2, 24-27
Leissinger et al.28 conducted a systematic re-
view of 14 studies. Half of these were retrospec-
tive in nature, and only one enrolled more than 
100 patients. In most of them, PCCs were ad-
ministered for major bleeding in patients under 
treatment with VKAs (three studies for intracra-
nial hemorrhage) or for urgent reversion of the 
anticoagulant effect. The following conclusions 
could be drawn:
 — Administration of PCCs to patients treat-
ed with VKAs rapidly reversed (within 30 min) 
the anticoagulant action to achieve an INR less 
than 1.3 in most patients, decreasing or stop-
ping bleeding, hematoma volume in intracranial 
hemorrhage, and transfusion rate. We therefore 
recommend use of PCCs for this indication (1B).
 — The reversing effect of PCCs was faster 
and more complete than that achieved with FFP, 
because doses close to 25-30 mL/kg of FFP are 
required to cause an effect similar to PCCs, and 
such doses may cause complications related to vol-
ume overload. We therefore recommend adminis-
tration of PCCs instead of FFP when immediate 
reversion of the effect of VKAs is required (1B).
 — A comparison of PCCs to vitamin K again 
confirmed the faster action of PCCs for reversing 
the anticoagulant effect. However, use of PCCs 
without concomitant vitamin K administration is 
Table III.—Differences between fresh frozen plasma and prothrombin complex concentrates.
FFP PPC
Volume to be administered Large
(approximately 30-fold greater)
Small
Availability Minimum 30 min Immediate
Administration rate Slow Fast (*)
Viral inactivation Methylene blue Two steps
Specific blood group Yes No
Risk of TRALI Yes No
Hypocalcemia by citrate Yes No
Thrombogenicity risk No Yes
Factor content All II, VII, IX, X
FFP: fresh frozen plasma; PCC: prothrombin complex concentrate; TRALI: transfusion-related acute lung injury.
(*) Infusion rate varies for the different PCCs, with accepted rates of 3 mL/min for Octaplex, 5 mL/min for Prothromplex 
NF, and a maximum of 8.4 mL/min for Beriplex).
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VII and at present, is the only one product avail-
able to control bleeding in hemophilia patients 
affected by high titre inhibitors to FVIII or FIX. 
The drug’s mechanism of action is now believed 
to be dependent on its content of prothrombin 
and FXa. The vial potency labelling is in arbi-
trary units of FVIII inhibitor bypassing units, 
where one unit of FEIBA shortens the activated 
partial thromboplastin time (aPTT) of high-titre 
FVIII reference plasma to 50% of the blank val-
ue. Empirically, FEIBA is administered at doses 
of 50–75 units/kg every 8–12 h, with a recom-
mended maximum daily dose of 200 units/kg.
For this potential indication, we suggest use of 
PCCs in the context of bleeding related to direct 
anticoagulants (2C), and recommend that they are 
not used as antidotes of direct anticoagulants (1C).
Severe liver failure
In patients with severe or fulminant liver fail-
ure in whom an invasive procedure is required, 
we suggest use of PCCs as a complement to other 
hemostatic drugs (2C).
Conditions for which use of PCCs is not rec-
ommended: prior allergic reactions to the com-
pound; pregnancy or puerperium (except in life-
threatening situations); patients with high risk of 
thrombosis. Thrombotic complications, includ-
ing venous thromboembolic disease (VTD) and 
disseminated intravascular coagulation (DIC), 
as well as other microvascular thromboses and 
acute coronary syndrome (ACS), have been re-
ported to occur in relation to administration of 
PCCs. Such complications were mainly, but not 
only, reported with administration of high doses 
(>200 IU/kg/day) and particularly in patients 
with severe liver disease (usually associated with 
antithrombin deficiency). To prevent these com-
plications, current PCC preparations include 
heparin and antithrombin or protein C in their 
composition.5, 41
Active or recent acute thrombotic event
Particularly in patients with a recent history 
(in the three months prior to administration) of 
any thrombotic event (acute coronary syndrome 
(ACS), stroke or VTD).41
Massive bleeding
PCCs have been used off-label for massive 
bleeding in patients undergoing prior cardiac, 
vascular, or other surgery.30, 31 Administration of 
PCCs in patients not responding to infusion of 
FFP, platelets, and cryoprecipitates allowed for 
achieving an adequate hemostasis in 78% of cas-
es, with a concomitant reduction in transfusion 
needs.32 Use of PCCs in multiple trauma patients 
with massive bleeding has also been proposed, 
and although use in such conditions is increas-
ing, no randomized studies allowing for advising 
routine use of PCCs in these patients are avail-
able.33-35 We therefore suggest use of PCCs in 
massive bleeding as a complement to FFP (2C).
Management of overdoses of direct anti-
coagulants (dabigatran, rivaroxaban, 
apixaban)
Some animal studies have shown that admin-
istration of activated PCC (Feiba®-Baxter SL) re-
verses the anticoagulant effect of direct thrombin 
inhibitors (DTI) or anti-FX agents.36 However, 
there are currently no specific antidotes for di-
rect antagonists of factors Xa or IIa. The exist-
ing recommendations are based on reports from 
experts or manufacturers themselves advising 
conservative measures, because of the short life 
of these compounds. Such measures may include 
administration of neutralizers (activated char-
coal, gastric lavage) in the event of an overdose. 
Monitoring of thrombin, ecarin, or activated 
partial thromboplastin times may be used as a 
guide of the pharmacological effect.37 Manage-
ment of severe hemorrhage related to adminis-
tration of direct anticoagulants should consist of 
replacement with adequate blood products. Use 
of FFP, PCCs, activated PCCs, or FVIIa may be 
warranted, but there are no specific recommen-
dations in this regard.38-40 FEIBA (an acronym 
for Factor Eight Inhibitor Bypassing Activity) 
anti-inhibitor coagulant complex (Baxter Bio-
science, Vienna, Austria) was the first activated 
PCCs developed and manipulated ex vivo to in-
crease the content of activated clotting factors, 
especially FVIIa. FEIBA contains factors II, IX 
and X mainly non-activated and activated factor 
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Dosage
The most adequate dose of PCCs has not 
been fully elucidated yet. However, as discussed 
above, PCC dosage should be individualized to 
maximize effectiveness, safety, and cost-effective-
ness, taking into account that hemostatic com-
petence is achieved with a plasma concentration 
of coagulation factors of approximately between 
30-40%.3, 18, 19, 44 The optimal dose should be 
calculated based on the following factors: clini-
cal status, prior INR, target INR, and weight 
of the patient. The duration and administra-
tion interval of the total calculated dose must 
be established based on the clinical and labora-
tory criteria of each individual patient, avoiding 
overcorrection, which is not necessary for many 
surgical procedures and may increase thrombot-
ic risk of the patient.
Based on these considerations and data from 
the literature for this review, we propose two 
methods, as an algorithm to calculate the dose 
that we administered (Figure 1) according to tar-
get INR, the patient’s weight, bleeding risk and 
the percentage of clotting factors to INR. And 
the other proposal (Figure 2) is to be applied to 
patients with VKAs treatments that require dif-
ferent types of surgery and according to severity.
The following method, modified from a pro-
posal by Schulman45, with three successive stages 
(Figure 1), could be used as a guide to calculate 
the dose to be administered:
1. Define the target INR, which will be de-
termined by the thrombotic-hemorrhagic risk 
balance in each patient. Thus, in patients with 
a high thrombotic risk and a moderate hemor-
rhagic risk, total correction of INR to maintain 
levels ranging from 1.5-2 may not be required.
2. Conversion of INR in a proportion of 
coagulation factors (expressed as a percentage 
of normal plasma). Thus, for instance, an INR 
ranging from 4 to 4.9 implies a concentration of 
approximately 10% of normal value.
3. Calculation of total dose of PCC to be ad-
ministered. The following formula is used to cal-
culate this: (target percentage of factors – prior 
percentage of factors) x patient body weight (kg) 
= IU of PCC. Thus, if an 80-kg patient has an 
initial INR of 4 (10% of factors) and the target 
Disseminated intravascular coagulation
In DIC there is a dreadful combination of 
thrombotic events and bleeding diathesis. Treat-
ment is based, among other measures, on admin-
istration of heparin in patients with clinical signs 
of thrombosis, and FFP and platelets in the event 
of bleeding. In these patients, administration of 
PCCs is not advised due to the procoagulant ca-
pacity of the product, except in life-threatening 
situations and in those where replacement of 
deficient coagulation factors by FFP is not suf-
ficient or feasible. Under these circumstances, 
antithrombin and/or heparin should preferably 
be administered before PCCs.28
Patients with a history of heparin-induced 
thrombocytopenia
PCC preparations contain very small amounts 
of heparin that could theoretically trigger HIT. 
No case has been reported to date.1
Side effects
PCCs are prohemostatic drugs and have 
therefore a potential to cause thromboembolic 
events. While their administration for approved 
indications is considered to be safe in most cases, 
some thromboembolic events have been report-
ed, including stroke, ACS, DIC, or VTD. Their 
actual incidence is not well documented and is 
reported to be approximately 2%, but this data 
should be analyzed in the context of the high 
thrombotic risk of patients usually treated with 
VKAs who require reversion with PCCs.5 The 
increase in the risk of occurrence of thrombotic 
episodes would also be related to the dose of 
PCC administered, and a maximum dose of 30 
IU/kg appears to be safe.42 However, in a series 
where doses greater than 40 IU/kg were used, no 
thrombotic complications were reported.43
Virus inactivation and/or eradication proce-
dures are used in the manufacturing process of 
PCCs (Tables II, III). While the possibility of 
transmission of infectious agents cannot be ruled 
out completely, PCCs should be considered a 
safe treatment in this regard.
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If the surgery is elective or if it is delayed more 
than 24 hours, prior suspension of anticoagulant 
therapy (including bridging anticoagulant ther-
apy with low molecular weight heparin) and the 
administration of vitamin K should be sufficient.
Protocol shown in Figure 2 proposes an algo-
rithm for management and use of PCCs when 
reversion of the effect of vitamin K antagonists 
is needed for “elective”, “urgent deferrable”, or 
“urgent-emergent” surgery.
After administration of PCCs for VKA rever-
sion, postoperative monitoring of INR values 
at 6-8 hours of surgery is required, with sys-
tematic assessment of hemostasis. In patients in 
INR is 1.5 (40% of factors), the dose will be: 
(40-10)x80 = 2400 IU of PCC.
PCC administration at doses adjusted based 
on calculation allows for rapid reversion (usually 
within 30 minutes) of the effect of VKAs, which 
is undoubtedly of vital importance in the case of 
bleeding and/or emergency surgery. Concomi-
tant administration of PCCs with intravenous 
vitamin K is recommended in most cases in or-
der to prolong the therapeutic effect of PCCs.
In the case of a life-threatening hemorrhage 
(e.g. intracranial hemorrhage), empiric admin-
istration at doses of 25-50 IU/kg should not be 
delayed waiting for the INR result.27
Figure 1.—Proposed algorithm to calculate the PCC dose to be administered in a bleeding patient and/or immediately before 
urgent surgery, based on patient’s clinical status, prior INR and target INR.P
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as safe preparations if they are used for their ap-
proved indications at the recommended dosage 
with adequate precautions for administration, 
and have been shown to be effective for reversing 
the effect of VKAs. Their adequate use based on 
decision algorithms in the perioperative setting 
allows a rapid normalization of INR for per-
forming emergency surgery, minimizing bleed-
ing risk. In patients with active bleeding related 
to treatment with VKAs, their administration ef-
fectively controls bleeding. PCCs have also been 
whom PCCs are indicated to reverse the effect of 
VKAs, bridging anticoagulation therapy should 
be started from 24 hours after surgery in the ab-
sence of active bleeding, with individualized as-
sessment of thrombotic and hemorrhagic risk in 
each patient.46
Conclusions
PCCs are medical products containing vari-
ous coagulation factors. They may be considered 
Figure 2.—Decision algorithm for reversing the action of oral anticoagulants depending on urgency of surgery.
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for emergency anticoagulation reversal: a prospective multi-
national clinical trial. J Thromb Hemost 2008;6:622-31.
Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis 
and thrombin regulation. Anesth Analg 2009;108:1433-46.
Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation manage-
ment – fresh frozen plasma. Best Practice & Research Clini-
cal Anesthesiology 2010;24:51-64.
20. Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen 
plasma is ineffective for correcting minimally elevated inter-
national normalized ratios. Transfusion 2005;45:1234-5.
21. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal 
FR, Preston EF. Emergency oral anticoagulant reversal: the 
relative efficacy of infusions of fresh frozen plasma and clot-
ting factor concentrate on correction of the coagulopathy. 
Thromb Hemost 1997;77:477-80.
22. Moog R, Reichenberg S, Hoburg A, Müller N. Qual-
ity of methylene-blue-treated fresh-frozen stored up to 27 
months. Transfusion 2010;50:516-8.
23. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin 
complex concentrate for oral anticoagulant reversal in neu-
rosurgical emergencies. Br J Neurosurg 2000;14:458-61.
24. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic 
management of patients treated with vitamin K antagonists. 
Anesthesiology 2008;109:918–26.
25. Grobler C, Callum JC, McCluskey SA. Reversal of vita-
min K antagonists prior to urgent surgery. Can J Anesth 
2010;57:458-67.
26. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández-
Mondéjar E, Gordini G et al. Management of bleeding fol-
lowing major trauma: a European guideline. Critical Care 
2007,11:R17.
27. Pernod G, Godier A, Gozalo C, Tremey B, Sié P. French clini-
cal practice guidelines on the management of patients on vita-
min K antagonists in at-risk situations (overdose, risk of bleed-
ing, and active bleeding). Thromb Res 2010;126:167-74.
28. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role 
of prothrombin complex concentrates in reversing warfarin 
anticoagulation: a review of the literature. Am J Hematol 
2008;83:137-43.
29. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of fac-
tor IX complex in warfarin-related intracranial hemorrhage. 
Neurosurgery 1999;45:1113-8.
30. Griffee MJ, DeLoughery TG, Thorborg PA. Coagulation 
management in massive bleeding. Curr Opin Anesthesiol 
2010;23:263-8.
31. Kozek-Langenecker S. Management of massive operative 
blood loss. Minerva Anestesiol 2007;73:401-15.
32. Bruce D, Nokes TJC. Prothrombin complex concentrate 
(Beriplex P/N) in severe bleeding: experience in a large ter-
tiary hospital. Crit Care 2008;12:R105.
33. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau 
J, Fernández-Mondéjar E et al. Management of bleeding 
following major trauma: an updated European guideline. 
Critical Care 2010;14:R52.
34. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor 
C, Scharbert G et al. Goal directed coagulation manage-
ment of major trauma patients using thromboelastometry 
(ROTEM)-guided administration of fibrinogen. Critical 
Care 2010;14:R55.
35. Cushing M, Shaz BH. Blood transfusion in trauma patients: 
unresolved questions. Minerva Anestesiol 2011;77:349-59.
36. Elg M, Carlsson S and Gustafsson D. Effect of Activated 
Prothrombin Complex concentrate or Recombinant Fac-
tor VIIa on the Bleeding Time and Thrombus Formation 
During Anticoagulation with a Direct Thrombin Inhibitor. 
Thromb Res 2001;101:145-57.
37. van Ryn J, Stangier J, Hertter S, Haertter S, Liesenfeld KH, 
Wienen W, Feuring M et al. Dabigatran etexilate--a novel, 
reversible, oral direct thrombin inhibitor:interpretation of 
coagulation assays and reversal of anticoagulant activity. 
Thromb Hemost 2010;103:1116-27.
used in bleeding patients with no VKA admin-
istration, in whom improvement on coagulation 
parameters could be associated with a significant 
better clinical evolution. In the future, this in-
dication may be added to the current ones, and 
PCCs may be part of the management and con-
trol protocols for bleeding patients, either due to 
multiple traumas or to any other condition.
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